Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Inclusion Criteria: * Recurrent or persistent cervical cancer after prior systemic chemotherapy for which there is no curative intent option * Documented histologic cervical cancer (acceptable histologies: squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma) * Patients must have PD-L1 tumor positivity as defined as CPS\>/= 1 * Age greater than 18 and ECOG performance status of \<= 2 * Adequate organ and marrow function Exclusion Criteria: * Prior treatment with cabozantinib or pembrolizumab * Receipt of any type of small molecule kinase inhibitor * Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy * Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery * Anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel) * Uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders: Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias Uncontrolled hypertension despite optimal antihypertensive treatment, stroke * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation * Clinically significant hematuria, hematemesis, or hemoptysis of \> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose * Active autoimmune disease requiring systemic therapy within the past 2 years * Active infection requiring systemic therapy within the past month * History of immunodeficiency